The estimated Net Worth of Vipin K Garg is at least $3.68 millió dollars as of 1 February 2024. Dr Garg owns over 35,495 units of Altimmune Inc stock worth over $2,153,897 and over the last 9 years he sold ALT stock worth over $626,300. In addition, he makes $897,696 as Pres és CEO & Director at Altimmune Inc.
Dr has made over 8 trades of the Altimmune Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 35,495 units of ALT stock worth $254,499 on 1 February 2024.
The largest trade he's ever made was exercising 35,495 units of Altimmune Inc stock on 1 February 2024 worth over $254,499. On average, Dr trades about 2,687 units every 26 days since 2015. As of 1 February 2024 he still owns at least 300,404 units of Altimmune Inc stock.
You can see the complete history of Dr Garg stock trades at the bottom of the page.
Dr. Vipin K. Garg Ph.D. is the Pres, CEO & Director at Altimmune Inc.
As the Pres és CEO & Director of Altimmune Inc, the total compensation of Dr D at Altimmune Inc is $897,696. There are no executives at Altimmune Inc getting paid more.
Dr D is 63, he's been the Pres és CEO & Director of Altimmune Inc since . There are 7 older and 5 younger executives at Altimmune Inc. The oldest executive at Altimmune Inc is David Drutz, 81, who is the Independent Director.
Vipin's mailing address filed with the SEC is 910 Clopper Road #201s, Gaithersburg, MD 20878, United States.
Over the last 7 years, insiders at Altimmune Inc have traded over $2,557,810 worth of Altimmune Inc stock and bought 3,362,060 units worth $23,898,779 . The most active insiders traders include Bioventures Ltd Novartis Ag..., Healthcare Capital Partners... és Mitchel Sayare. On average, Altimmune Inc executives and independent directors trade stock every 35 days with the average trade being worth of $432,889. The most recent stock trade was executed by David Drutz on 19 August 2024, trading 41,750 units of ALT stock currently worth $106,463.
altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current
Altimmune Inc executives and other stock owners filed with the SEC include: